Evaluating the effect of empagliflozin on blood pressure, cardiovascular events, mortality and renal parameters in patients undergoing coronary artery bypass surgery admitted to the A coronary care unit

Evaluating the effect of empagliflozin on blood pressure, cardiovascular events, mortality and renal parameters in patients undergoing coronary artery bypass surgery

Double-blind, randomized, placebo-controlled clinical

This study will be conducted in the intensive care unit of Afshar Hospital in Yazd. The patients will be divided into two groups receiving Empagliflozin tablet and placebo by random permutation block method. Each patient will be identified with a number and the list of numbers of people who should be placed in each group will be given to the nurses and the participants, researchers, doctors And the data collectors will be unaware of this list.

Input criteria include:Patients undergoing coronary artery bypass surgery Not being allergic to empagliflozin Exclusion criteria include:Patients who cannot get enough information with echocardiography History of taking pioglitazone at least 8 weeks before entering the study Glomerular filtration rate less than 30 mg per minute per 1.73 square meters of body surface based on the CKD-EPI formula Pregnant or lactating women

intervention group: Recipients of empagliflozin 10 mg tablets from Abidi Pharmaceutical Company receive one empagliflozin tablet orally a few hours after coronary artery bypass surgery to reduce blood pressure, cardiovascular events, mortality, and control kidney parameters control group: The recipients of a placebo prepared in the pharmaceutical laboratory of the Yazd Faculty of Pharmacy in the same size and color as the empagliflozin tablet, a few hours after coronary bypass surgery, take a 10 mg tablet orally to reduce blood pressure, cardiovascular events, mortality and Renal controls

The rate of reduction of blood pressure, cardiovascular events, mortality and control of renal parameters

The patients are divided into 25-person groups.using the statistical software,25 out of 50 patients are randomly assigned to treatment group and 25 to placebo group. Unit of randomization: lndividual. Tools used in randomization:computer software

In this study, the participants, the principle investigator, the physicians and the data collectors are blinded. The patients who are going to receive the drug or placebo , are determined by numbers and these numbers are given to the head nurse and nurses of surgery department.